Owen Hughes currently serves as an MPM Advisor and CEO of Cullinan Oncology (NASDAQ: CGEM), an MPM portfolio company that focuses on developing high-value cancer therapeutics using a cost-efficient business model.
Prior to MPM, Owen served as the Chief Business Officer and Head of Corporate Development at Intarcia Therapeutics, where he was responsible for financing, M&A, business development and operations. Prior to Intarcia, he served as a Director of Brookside Capital, a hedge fund under the Bain Capital umbrella, managing public and private healthcare investments. Prior to his tenure at Brookside, Owen was Senior Portfolio Manager at Pyramis Global Advisors, a Fidelity Investments Company. He has more than 16 years of Wall Street experience, on both the buy- and sell-side. Owen is currently the chairman of the board at Radius Health and a director at Translate Bio and Wren Therapeutics.
Owen received his B.A. from Dartmouth College